Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age. Issue 31 (17th July 2015)

• Record Type: Journal Article
• Authors: Janssen, Julia M.; Jackson, Sam; Heyward, William L.; Janssen, Robert S.
• Is Part Of: Vaccine. Volume 33:Issue 31(2015)
• Page Start: 3614
• Page End: 3618
• Publication Date: 2015-07-17
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.05.070
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Phase 3 trial data of an investigational hepatitis B vaccine in subpopulations.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">HBsAg-1018 induced higher seroprotection rates than HBsAg-Eng.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">HBsAg-1018 demonstrated better consistency of SPRs in subpopulations than HBsAg-Eng.</p> </list-item> </list> </p> </sec> </abstract>